Your browser is no longer supported. Please, upgrade your browser.
OPT [NASD]
Opthea Limited
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand42.21M Perf Week-7.78%
Market Cap320.36M Forward P/E- EPS next Y- Insider Trans- Shs Float22.66M Perf Month8.27%
Income- PEG- EPS next Q- Inst Own21.19% Short Float0.60% Perf Quarter-8.55%
Sales0.23M P/S1403.52 EPS this Y- Inst Trans- Short Ratio4.29 Perf Half Y-20.11%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year73.13%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range6.41 - 17.86 Perf YTD-32.32%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-57.49% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low18.50% ATR0.43
Employees- Current Ratio- Sales Q/Q28.80% Oper. Margin- RSI (14)46.27 Volatility5.65% 5.23%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.08 Prev Close7.84
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume31.71K Price7.59
Recom1.20 SMA20-3.57% SMA500.39% SMA200-20.98% Volume2,614 Change-3.19%
Nov-17-20Initiated Citigroup Buy $48
Nov-11-20Initiated Truist Buy $25
Nov-11-20Initiated SVB Leerink Outperform $33
Nov-11-20Initiated Oppenheimer Outperform $36
Sep-07-21 08:20PM  
Sep-02-21 07:00AM  
Aug-30-21 07:00AM  
Aug-10-21 07:00AM  
Aug-09-21 07:00AM  
Jul-06-21 07:00AM  
Jun-16-21 04:06PM  
Jun-15-21 12:27PM  
Jun-14-21 07:00AM  
Jun-01-21 07:11AM  
May-31-21 04:27PM  
Apr-06-21 05:30AM  
Mar-31-21 05:30AM  
Mar-15-21 05:30AM  
Mar-10-21 05:30AM  
Mar-02-21 02:20PM  
Feb-24-21 05:30AM  
Feb-17-21 05:30AM  
Oct-20-20 09:38PM  
Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3 for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.